Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|March 9, 2023
Vetter Joins United Nations Global Compact
Author(s)Alivia Leon
Vetter has become a participant of the UN Global Compact Network.
Advertisement
Vetter announced on March 6, 2023 that is has become a participant of the UN Global Compact Network. The UN Global Compact was launched in 2000 and is the largest corporate initiative on sustainable business worldwide. More than 15,000 companies and 3000 non-profit organizations from over 160 countries have signed the initiative to date.
A main focus of the UN Global Compact is on the enforcement and implementation of human and employee rights, environmental protection, and the prevention of corruption. By becoming a participant, Vetter gains access to the large network of companies and organizations that are committed to the same corporate goals. Vetter will submit a publicly viewable annual progress report, which will serve as evidence of transparency and accountability.
"As a family-owned business in the healthcare sector, we bear great responsibility,” said Henryk Badack, senior vice president, technical service and internal project management, in a company press release. “And we believe in the power of cooperation. The UN Global Compact combines these two approaches very well and is also a strong commitment to shared values and goals across business sectors and national borders."
Source:
Advertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement